IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Amphastar Pharmaceuticals, Inc. (“Amphastar” or the “Company”) (Nasdaq: AMPH) concerning possible violations of federal securities laws.
If you purchased shares of Amphastar and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
Amphastar announced that its company Armstrong Pharmaceuticals, Inc. ("Armstrong") received notice from the U.S. Food and Drug Administration ("FDA"), revealing to Armstrong that its New Drug Application for Primatene Mist, an epinephrine inhalation aerosol product, would not be approved. The FDA encouraged Armstrong to implement changes to the product's label and packaging. The FDA also suggested that Armstrong complete another Human Factor validation study to assess client ability to use the product independently of a doctor or pharmacist.
When this information was revealed to the public, the value of Amphastar fell, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.